Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt No Debt
GALT's Cash to Debt is ranked higher than
94% of the 801 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.70 vs. GALT: No Debt )
GALT' s 10-Year Cash to Debt Range
Min: 0.41   Max: No Debt
Current: No Debt

Interest Coverage No Debt
GALT's Interest Coverage is ranked higher than
85% of the 484 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 76.05 vs. GALT: No Debt )
GALT' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: -7.66
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
ROE (%) -57.84
GALT's ROE (%) is ranked lower than
52% of the 796 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.00 vs. GALT: -57.84 )
GALT' s 10-Year ROE (%) Range
Min: -830.47   Max: -63.92
Current: -57.84

-830.47
-63.92
ROA (%) -43.01
GALT's ROA (%) is ranked lower than
53% of the 809 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. GALT: -43.01 )
GALT' s 10-Year ROA (%) Range
Min: -1711.47   Max: -50.18
Current: -43.01

-1711.47
-50.18
ROC (Joel Greenblatt) (%) -728400.00
GALT's ROC (Joel Greenblatt) (%) is ranked lower than
57% of the 805 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 15.22 vs. GALT: -728400.00 )
GALT' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -403466.67   Max: -1857.06
Current: -728400

-403466.67
-1857.06
EBITDA Growth (%) 11.50
GALT's EBITDA Growth (%) is ranked higher than
79% of the 639 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.80 vs. GALT: 11.50 )
GALT' s 10-Year EBITDA Growth (%) Range
Min: -22.1   Max: 11.5
Current: 11.5

-22.1
11.5
EPS Growth (%) 11.80
GALT's EPS Growth (%) is ranked higher than
78% of the 624 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.70 vs. GALT: 11.80 )
GALT' s 10-Year EPS Growth (%) Range
Min: -33.2   Max: 35.1
Current: 11.8

-33.2
35.1
» GALT's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

GALT Guru Trades in

GALT Guru Trades in

Q1 2014

GALT Guru Trades in Q1 2014

George Soros 48,200 sh (New)
» More
Q2 2014

GALT Guru Trades in Q2 2014

George Soros Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with GALT

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2014-06-30 Sold Out 0.01%$10.23 - $14.81 $ 5.97-52%0
George Soros 2014-03-31 New Buy0.01%$8.025 - $18.3 $ 5.97-57%48200
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.19
GALT's P/B is ranked higher than
61% of the 828 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.60 vs. GALT: 5.19 )
GALT' s 10-Year P/B Range
Min: 0   Max: 457.5
Current: 5.19

0
457.5
EV-to-EBIT -7.80
GALT's EV-to-EBIT is ranked lower than
56% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 31.14 vs. GALT: -7.80 )
GALT' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -7.8

Current Ratio 16.07
GALT's Current Ratio is ranked higher than
97% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.46 vs. GALT: 16.07 )
GALT' s 10-Year Current Ratio Range
Min: 0.2   Max: 20.63
Current: 16.07

0.2
20.63
Quick Ratio 16.07
GALT's Quick Ratio is ranked higher than
98% of the 650 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.80 vs. GALT: 16.07 )
GALT' s 10-Year Quick Ratio Range
Min: 0.2   Max: 20.63
Current: 16.07

0.2
20.63

Valuation & Return

vs
industry
vs
history
Price/Net Cash 5.10
GALT's Price/Net Cash is ranked higher than
97% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. GALT: 5.10 )
GALT' s 10-Year Price/Net Cash Range
Min: 4.96   Max: 221
Current: 5.1

4.96
221
Price/Net Current Asset Value 5.24
GALT's Price/Net Current Asset Value is ranked higher than
95% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 9999.00 vs. GALT: 5.24 )
GALT' s 10-Year Price/Net Current Asset Value Range
Min: 4.96   Max: 732
Current: 5.24

4.96
732
Price/Tangible Book 5.19
GALT's Price/Tangible Book is ranked higher than
69% of the 831 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.11 vs. GALT: 5.19 )
GALT' s 10-Year Price/Tangible Book Range
Min: 4.87   Max: 516
Current: 5.19

4.87
516
Forward Rate of Return (Yacktman) -4.93
GALT's Forward Rate of Return (Yacktman) is ranked higher than
62% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.93 vs. GALT: -4.93 )
GALT' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0   Max: 0
Current: -4.93

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare:TKPYY, TEVA, AGN, FRX, MRX » details
Traded in other countries:PHPN.Germany
Galectin Therapeutics Inc was incorporated in Nevada on January 26, 2001 as DTR-Med Pharma Corp. On May 10, 2001, DTR changed its name to Pro- Pharmaceuticals, Inc. On May 26, 2011, Pro-Pharmaceuticals, Inc. changed its name to Galectin Therapeutics Inc. Galectin Therapeutics is a development-stage company, which is engaged in drug development to create new therapies for cancer and fibrotic disease. The Company's drug candidates are based on its method of targeting galectin proteins, which are key mediators of biologic and pathologic function. The Company uses naturally occurring plant materials to create complex carbohydrates with specific molecular weights and pharmaceutical properties. The Company focuses on diseases with serious, life-threatening consequences to patients and those where current treatment options are limited. The Company has two compounds in development, one intended to be used in cancer therapy and the other intended to be used in the treatment of liver fibrosis and fatty liver disease. These two compounds are produced from completely different natural starting materials, both possessing the property which lends itself to binding to and inhibiting galectin proteins. GM-CT-01, its product candidate for cancer therapy, is a proprietary linear polysaccharide polymer comprised of mannose and galactose that has a precisely defined chemical structure and is derived from a plant source. GR-MD-02, its other product for treatment of liver fibrosis and fatty liver disease with inflammation and fibrosis, is a proprietary complex polysaccharide polymer possessing both linear and globular structures, which also is derived from a plant source. Its competitors include major multinational pharmaceutical and chemical companies, specialized biotechnology firms and universities and other research institutions. The research, development, testing, manufacture, labeling, promotion, advertising, distribution, and marketing, among other things, of its products are extensively regulated by governmental authorities in the United States and other countries.
» More Articles for GALT

Headlines

Articles On GuruFocus.com
No related article found.

More From Our Partners
MLV & Co Has Positive Outlook On Galectin Therapeutics Inc Sep 16 2014 - BENZINGA

More From Other Websites
Nasdaq stocks posting largest percentage increases Sep 17 2014
MLV & Co Has Positive Outlook On Galectin Therapeutics Inc Sep 16 2014
GALECTIN SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Reminds... Sep 15 2014
8:02 am Galectin Therapeutics announces issuance of U.S. patent for GR-MD-02 in diabetic... Sep 15 2014
Galectin Therapeutics Announces Issuance of U.S. Patent for GR-MD-02 in Diabetic Nephropathy Sep 15 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Sep 15 2014
GALECTIN THERAPEUTICS INC Files SEC form 8-K, Other Events, Financial Statements and Exhibits Sep 12 2014
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of Galectin Therapeutics Inc. Of... Sep 12 2014
SHAREHOLDER ALERT: LEVI & KORSINSKY, LLP Reminds Investors of Class Action Against Galectin... Sep 10 2014
Galectin Therapeutics to Present at Aegis Capital Corporation 2014 Healthcare and Technology... Sep 10 2014
Hagens Berman Reminds Investors in Galectin Therapeutics, Inc. of the Sept. 29, 2014 Lead Plaintiff... Sep 08 2014
SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action against Galectin... Sep 05 2014
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From... Sep 04 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses In Excess Of $100,000 Investing In... Aug 29 2014
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Reminds Investors of Class Action Against Galectin... Aug 28 2014
Autohome, BitAuto Come Down From Monday Highs Aug 27 2014
Deadline in Lawsuit for Investors in Galectin Therapeutics Inc. (GALT) Shares Over Alleged... Aug 26 2014
EQUITY ALERT: Rosen Law Firm Reminds Galectin Therapeutics, Inc. Investors of Important Class Action... Aug 25 2014
Hagens Berman Advises Investors in Galectin Therapeutics, Inc. of the Sept. 29, 2014 Lead Plaintiff... Aug 25 2014
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in... Aug 23 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK